Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 19/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 13/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 0.74 |
| ▸ | IL1B | P01584 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thalidomide SCHEMBL7581 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL410642 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL15197560 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL41641 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL455269 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411178 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411175 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL23420695 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL22772286 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL19586750 | 0.98 | CRBN (0.97) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124510-A | PROTAC molecule, preparation method and application thereof | 广州医科大学 | 2022-09-30 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-110498788-A | A kind of preparation method of high-purity thalidomide alpha-crystal form | CINKATE PHARM TECH SHANGHAI CO LTD | 2019-11-26 | — | — | CN | disclosed |
| US-10426740-B1 | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues | AVM BIOTECHNOLOGY, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3530274-A1 | DEXAMETHASONE TO REDUCE STEM CELL ACCUMULATION IN THE SPLEEN | Deisher, Theresa (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2605765-B1 | DEXAMETHASONE FOR USE IN TREATING OSTEOARTHRITIS, LIVER FAILURE, TYPE-2 DIABETES MELLITUS, STROKE AND PARKINSON'S DISEASE, IN COMBINATION WITH STEM CELL TREATMENT | DEISHER THERESA (US) | 2019-05-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9962408-B2 | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues | AVM BIOTECHNOLOGY LLC (US) | 2018-05-08 | — | — | US | disclosed |
| CN-107033243-A | CD38 antibody for treating Huppert's disease | 根马布股份公司 | 2017-08-11 | — | — | CN | disclosed |
| US-20170128493-A1 | COMPOSITIONS AND METHODS TO INHIBIT STEM CELL AND PROGENITOR CELL BINDING TO LYMPHOID TISSUE AND FOR REGENERATING GERMINAL CENTERS IN LYMPHATIC TISSUES | AVM BIOTECHNOLOGY, LLC | 2017-05-11 | — | — | US | disclosed |
| EP-1684758-A4 | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES. | CELGENE CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1755599-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1755599-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005102333-A9 | METHODS OF USING AND COMPOSITIONS COMPRISING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORP (US) | 2007-01-25 | — | — | WO | disclosed |
| EP-1684758-A2 | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES. | CELGENE CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005102333-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005046686-A1 | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046593-A2 | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES. | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1343500-A2 | COMPOSITIONS COMPRISING TEMOZOLOMIDE AND THALIDOMIDE AND METHODS FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002043720-A2 | COMPOSITIONS COMPRISING TEMOZOLOMIDE AND THALIDOMIDE AND METHODS FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-06 | — | — | WO | disclosed |